Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas
Cancer, 05/31/2012
Clinical Article
Ferrario A et al. – Rituximab, fludarabine, and cyclophosphamide (FCR) induction therapy followed by a short maintenance phase is a highly effective regimen with acceptable toxicity.



